Literature DB >> 1901319

Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits.

J Haarbo1, P Leth-Espensen, S Stender, C Christiansen.   

Abstract

Cardiovascular disease is currently the leading cause of death among women in the United States. To investigate the effect of postmenopausal hormone therapy on atherogenesis, we studied 75 cholesterol-fed female rabbits for 19 wk. The rabbits were randomly assigned to five groups. Four groups underwent bilateral ovariectomy followed by treatment with either 17 beta-estradiol, 17 beta-estradiol plus norethisterone acetate, 17 beta-estradiol plus levonorgestrel, or placebo. The fifth group had a sham operation and received placebo. The hormone groups had only one-third of the aortic accumulation of cholesterol found in the placebo groups, a difference that was highly statistically significant (P less than 0.0001). No significant differences in aortic accumulation of cholesterol were found in the hormone groups. This indicates that estrogen attenuates atherogenesis in cholesterol-fed ovariectomized rabbits and that two commonly prescribed progestogens do not counteract the effect. The beneficial effect of estradiol could only partly be explained by its lowering effects on serum total cholesterol or VLDL cholesterol, which implies that estradiol possesses additional beneficial effects, possibly a direct action on the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901319      PMCID: PMC295153          DOI: 10.1172/JCI115129

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

Review 1.  Cardiovascular benefits of estrogen replacement therapy.

Authors:  R K Ross; A Paganini-Hill; T M Mack; B E Henderson
Journal:  Am J Obstet Gynecol       Date:  1989-05       Impact factor: 8.661

2.  From menarche to menopause: coronary artery atherosclerosis and protection in cynomolgus monkeys.

Authors:  T B Clarkson; M R Adams; J R Kaplan; C A Shively; D R Koritnik
Journal:  Am J Obstet Gynecol       Date:  1989-05       Impact factor: 8.661

3.  Pharmacokinetics of progestational compounds.

Authors:  K Fotherby
Journal:  Maturitas       Date:  1986-07       Impact factor: 4.342

4.  The measurement of secretory endometrial protein PP14 in serum from postmenopausal women receiving unopposed estrogen or continuously combined estrogen/progestogen.

Authors:  I Byrjalsen; B J Riis; C Christiansen
Journal:  Gynecol Endocrinol       Date:  1989-06       Impact factor: 2.260

Review 5.  Cholesterol, lipoproteins, and coronary heart disease in women.

Authors:  T L Bush; L P Fried; E Barrett-Connor
Journal:  Clin Chem       Date:  1988       Impact factor: 8.327

6.  Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.

Authors:  I Persson; H O Adami; L Bergkvist; A Lindgren; B Pettersson; R Hoover; C Schairer
Journal:  BMJ       Date:  1989-01-21

7.  Oestrogen-induced changes in lipoprotein metabolism: role in prevention of atherosclerosis in the cholesterol-fed rabbit.

Authors:  P Henriksson; M Stamberger; M Eriksson; M Rudling; U Diczfalusy; L Berglund; B Angelin
Journal:  Eur J Clin Invest       Date:  1989-08       Impact factor: 4.686

8.  Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol.

Authors:  P T Ma; T Yamamoto; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

9.  Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits.

Authors:  J L Hough; D B Zilversmit
Journal:  Arteriosclerosis       Date:  1986 Jan-Feb

Review 10.  Noncontraceptive estrogen use and cardiovascular disease.

Authors:  T L Bush; E Barrett-Connor
Journal:  Epidemiol Rev       Date:  1985       Impact factor: 6.222

View more
  15 in total

1.  Estradiol attenuates directed migration of vascular smooth muscle cells in vitro.

Authors:  F D Kolodgie; A Jacob; P S Wilson; G C Carlson; A Farb; A Verma; R Virmani
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 2.  Sex steroids and the cardiovascular system.

Authors:  C Christiansen
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits.

Authors:  P Holm; N Korsgaard; M Shalmi; H L Andersen; P Hougaard; S O Skouby; S Stender
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

4.  Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice.

Authors:  R H Karas; J B Hodgin; M Kwoun; J H Krege; M Aronovitz; W Mackey; J A Gustafsson; K S Korach; O Smithies; M E Mendelsohn
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 5.  The Estrogen Receptor α-Cistrome Beyond Breast Cancer.

Authors:  Marjolein Droog; Mark Mensink; Wilbert Zwart
Journal:  Mol Endocrinol       Date:  2016-08-04

6.  Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice.

Authors:  J B Hodgin; J H Krege; R L Reddick; K S Korach; O Smithies; N Maeda
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

7.  Anti-atherogenicity in women does not prevent restenosis after balloon angioplasty.

Authors:  T Watanabe; S Isoyama; A Nakamura; K Shirato; H Kubota; N Sekiguchi; F Sato; A Katoh; K Munakata; M Sugi; E Nozaki; O Nishioka; K Tamaki; K Akai; T Araki; K Yokoyama
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

8.  Hormone Therapy Use and Risk of Chronic Disease in the Nurses' Health Study: A Comparative Analysis With the Women's Health Initiative.

Authors:  Shilpa N Bhupathiraju; Francine Grodstein; Bernard A Rosner; Meir J Stampfer; Frank B Hu; Walter C Willett; JoAnn E Manson
Journal:  Am J Epidemiol       Date:  2017-09-15       Impact factor: 4.897

Review 9.  Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.

Authors:  Marius Jan van der Mooren; Peter Kenemans
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Tibolone inhibits aortic atherosclerotic lesionformation in oophorectomized cholesterol-fed rabbits.

Authors:  Camil Castelo-Branco; Alex Sanjuán; Carles Ascaso; Marta Colodrón; Juan Enrique Blümel; Elena Casals; Jaume Ordi; Juan Antonio Vanrell
Journal:  Exp Clin Cardiol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.